Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Kimihisa Ueno"'
Publikováno v:
Journal of Pharmacological Sciences, Vol 95, Iss 2, Pp 291-293 (2004)
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-me
Externí odkaz:
https://doaj.org/article/41150b8b1a8d49f985158020929e1473
Autor:
Yuichi Takahashi, Satoshi Shuto, Jun-Ichi Saito, Kimihisa Ueno, Tomohiro Tamura, Michihiko Suzuki, Kazuki Henmi, Masahiro Matsubara, Takeshi Kuboyama, Yamamoto Keisuke, Arata Yanagisawa
Publikováno v:
Journal of Medicinal Chemistry. 61:10067-10083
A novel class of PPARγ ligand 1 (EC50 = 197 nM) with a dibenzoazepin scaffold was identified through high-throughput screening campaign. To avoid the synthetically troublesome chiral center of 1, its conformational analysis using the MacroModel was
Autor:
Shintaro Hosoe, Hiroshi Kodaira, Masahiro Matsubara, Jun-Ichi Saito, Kimihisa Ueno, Takeshi Uemori, Yuichi Takahashi, Tomohiro Tamura, Keiko Nagata, Yamamoto Keisuke, Michihiko Suzuki, Nakamura Rina, Satoshi Shuto
Publikováno v:
Bioorganic & Medicinal Chemistry / Bioorganic and Medicinal Chemistry. 27(22):115122
We previously identified dibenzooxepine derivative 1 as a potent PPARγ ligand with a unique binding mode owing to its non-thiazolidinedione scaffold. However, while 1 showed remarkably potent MKN-45 gastric cancer cell aggregation activity, an indic
Autor:
Etsuo Ohshima, Hiromasa Miyaji, Hideki Mimura, Toshihide Ikemura, Akira Karasawa, Haruhiko Manabe, Masatsugu Sawada, Eiichi Fuse, Kimihisa Ueno, Osamu Kotera, Satoshi Tashiro
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 314:244-251
Prostaglandin (PG) D2, a major cyclooxygenase metabolite generated from immunologically stimulated mast cells, is known to induce activation and chemotaxis in eosinophils, basophils, and T helper 2 (Th2) lymphocytes via a newly identified PGD2 recept
Autor:
Kimihisa Ueno, Takao Nakajima, Satoshi Nakanishi, Kotaro Takasaki, Katsuya Higo, Miho Iwase, Yuji Nomoto
Publikováno v:
European Journal of Pharmacology. 486:335-342
Dipeptidyl peptidase IV inhibitors are expected to be categorized in a new type of antidiabetic drugs. We had developed a long-acting dipeptidyl peptidase IV inhibitor, K579 [(S)-1-[4-methyl-1-(2-pyrimidinyl)-4-piperidylamino]acetyl-2-pyrrolidinecarb
Publikováno v:
Synthesis. 1997:1446-1450
Publikováno v:
Journal of Pharmacological Sciences, Vol 95, Iss 2, Pp 291-293 (2004)
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-me
Publikováno v:
European journal of pharmacology. 505(1-3)
K579 ((S)-1-[4-methyl-1-(2-pyrimidinyl)-4-piperidylamino]acetyl-2-pyrrolidinecarbonitrile), which is a long-acting and a slow binding dipeptidyl peptidase IV inhibitor, preserved the endogenously secreted active forms of glucagon-like peptide-1, augm